Jip M van Elst1, Nikki S IJzerman2,3, Ron H J Mathijssen2, Neeltje Steeghs3, Anna K L Reyners1, Jacco J de Haan4. 1. Department of Medical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, the Netherlands. 2. Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands. 3. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 4. Department of Medical Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, the Netherlands. j.j.de.haan@umcg.nl.
Abstract
CONTEXT: Taste, smell, and mouthfeel disturbances are underrated and underreported, but important side effects of anti-cancer medication. These symptoms are associated with a lower quality of life (QoL). The prevalence and the impact of taste, smell, and mouthfeel disturbances on daily life in patients with a gastrointestinal stromal tumor (GIST) are largely unknown. OBJECTIVES: This exploratory study assessed the prevalence and type of taste, smell, and mouthfeel disturbances and their impact on daily life and QoL in patients with a GIST treated with a tyrosine-kinase inhibitor (TKI). METHODS: Patients currently treated with TKIs for GIST completed a standardized questionnaire. The questionnaire addressed changes in taste, smell, and mouthfeel and, if changes occurred, impact on daily life and QoL. Statistics are descriptive. RESULTS: A total of 65 GIST patients on TKI treatment completed the questionnaire. Of these patients, 79%, 12%, and 9% currently used imatinib, sunitinib, and regorafenib respectively. Taste, smell, and mouthfeel disturbances were reported by 25 (38%), 15 (23%), and 36 (55%) patients respectively. Salty and sweet tastes were mostly affected, respectively in 14 and 13 patients. A dry mouth was experienced by 29 (45%) patients. Taste disturbances were more often reported to have impact on daily life and QoL (80% and 60%) than smell (47% and 31%) and mouthfeel disturbances (47% and 30%). CONCLUSION: Taste, smell, and mouthfeel disturbances are frequent side effects of TKIs in GIST patients. Daily life and QoL are affected in a considerable number of those patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NL7827 (2019-06-25).
CONTEXT: Taste, smell, and mouthfeel disturbances are underrated and underreported, but important side effects of anti-cancer medication. These symptoms are associated with a lower quality of life (QoL). The prevalence and the impact of taste, smell, and mouthfeel disturbances on daily life in patients with a gastrointestinal stromal tumor (GIST) are largely unknown. OBJECTIVES: This exploratory study assessed the prevalence and type of taste, smell, and mouthfeel disturbances and their impact on daily life and QoL in patients with a GIST treated with a tyrosine-kinase inhibitor (TKI). METHODS: Patients currently treated with TKIs for GIST completed a standardized questionnaire. The questionnaire addressed changes in taste, smell, and mouthfeel and, if changes occurred, impact on daily life and QoL. Statistics are descriptive. RESULTS: A total of 65 GIST patients on TKI treatment completed the questionnaire. Of these patients, 79%, 12%, and 9% currently used imatinib, sunitinib, and regorafenib respectively. Taste, smell, and mouthfeel disturbances were reported by 25 (38%), 15 (23%), and 36 (55%) patients respectively. Salty and sweet tastes were mostly affected, respectively in 14 and 13 patients. A dry mouth was experienced by 29 (45%) patients. Taste disturbances were more often reported to have impact on daily life and QoL (80% and 60%) than smell (47% and 31%) and mouthfeel disturbances (47% and 30%). CONCLUSION: Taste, smell, and mouthfeel disturbances are frequent side effects of TKIs in GIST patients. Daily life and QoL are affected in a considerable number of those patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NL7827 (2019-06-25).
Authors: Allan J Hovan; P Michele Williams; Peter Stevenson-Moore; Yula B Wahlin; Kirsten E O Ohrn; Linda S Elting; Fred K L Spijkervet; Michael T Brennan Journal: Support Care Cancer Date: 2010-05-22 Impact factor: 3.603
Authors: A van der Werf; M Rovithi; J A E Langius; M A E de van der Schueren; H M W Verheul Journal: Eur J Cancer Date: 2017-10-04 Impact factor: 9.162
Authors: August Zabernigg; Eva-Maria Gamper; Johannes M Giesinger; Gerhard Rumpold; Georg Kemmler; Klaus Gattringer; Barbara Sperner-Unterweger; Bernhard Holzner Journal: Oncologist Date: 2010-07-28
Authors: Kjetil Søreide; Oddvar M Sandvik; Jon Arne Søreide; Vanja Giljaca; Andrea Jureckova; V Ramesh Bulusu Journal: Cancer Epidemiol Date: 2015-11-24 Impact factor: 2.984
Authors: Samantha C Sodergren; Alice White; Fabio Efficace; Mirjam Sprangers; Deborah Fitzsimmons; Andrew Bottomley; Colin D Johnson Journal: Crit Rev Oncol Hematol Date: 2014-01-17 Impact factor: 6.312
Authors: Anna Boltong; Sanchia Aranda; Russell Keast; Rochelle Wynne; Prudence A Francis; Jacqueline Chirgwin; Karla Gough Journal: PLoS One Date: 2014-07-31 Impact factor: 3.240
Authors: Y C de Vries; S Boesveldt; C S Kelfkens; E E Posthuma; M M G A van den Berg; J Th C M de Kruif; A Haringhuizen; D W Sommeijer; N Buist; S Grosfeld; C de Graaf; H W M van Laarhoven; E Kampman; R M Winkels Journal: Breast Cancer Res Treat Date: 2018-02-23 Impact factor: 4.872